Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.
Filter Awards
Disease |
Cell Type | Therapeutic or Technology | Institution | Stage | Project Objective | Details |
|---|---|---|---|---|---|---|
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Donor cell therapy | Celularity Inc |
 |
Clinical Trial, Phase 1 or Phase 1/2 | |
|
COVID-19, Respiratory Disorders |
iPS Cell | Small molecule therapy | Sanford-Burnham |
 |
Development Candidate, Proof of Concept | |
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Biologic | UCSD |
|
Development Candidate, Proof of Concept | |
| COVID-19 | iPS Cell | Small molecule therapy | UCSD |
|
Development Candidate, Proof of Concept | |
| COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
| COVID-19 |
Embryonic Stem Cell, iPS Cell |
Gene-modified, donor cell therapy | COH |
|
Proof of Concept | |
|
Cystinosis, Kidney Failure |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Dementia | iPS Cell | Donor cell therapy | Gladstone |
|
Development Candidate, Proof of Concept | |
| Duchenne Muscular Dystrophy | Somatic Cell | Gene Therapy, cell free | MyoGene Bio LLC |
 |
Pre-IND/IDE or Equivalent | |
| Epidermolysis Bullosa | iPS Cell | Gene-modified, personalized cell therapy | Stanford |
|
Development Candidate, Proof of Concept | |
| Epidermolysis Bullosa | iPS Cell | Gene-modified, personalized cell therapy | Stanford |
|
Pre-IND/IDE or Equivalent | |
| Hearing Loss | Adult Stem Cell | Protein/peptide therapy | Stanford |
|
Development Candidate, Proof of Concept | |
| Heart failure | iPS Cell | Exosomes based therapy | Stanford |
|
Development Candidate, Proof of Concept | |
| Heart failure | Embryonic Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Hemophilia A | Adult Stem Cell | Gene modification | COH |
|
Development Candidate, Proof of Concept | |
|
HIV-related Lymphoma, HIV/AIDS |
Adult Stem Cell | Gene-modified, personalized cell therapy | UC Davis |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
HIV/AIDS, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| HIV/AIDS | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| HIV/AIDS | Personalized cell therapy | COH |
 |
IND | ||
| Huntington's Disease | Embryonic Stem Cell | Donor cell therapy | UC Irvine |
|
IND | |
|
Hyper IgM Syndrome, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
|
Immune Disease, Leukocyte Adhesion Deficiency |
Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, X-linked Chronic Granulomatous Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, Severe Combined Immunodeficiency, X-linked (X-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | St. Jude |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | Orchard Therapeutics |
 |
Clinical Trial, Phase 2 | |
| Inflammatory bowel disease | Adult Stem Cell | Donor cell therapy | Vitabolus, Inc. |
|
Development Candidate, Proof of Concept | |
|
Intestinal Disease, Neurological Disorders |
iPS Cell | Donor cell therapy | CHLA |
|
Pre-IND/IDE or Equivalent | |
|
IPEX Syndrome, Immune Disease |
Vital Research Opportunity | Gene Therapy, cell free | Stanford |
|
IND | |
| IPEX Syndrome | Adult Stem Cell | Gene-modified, personalized cell therapy | ImmunoVec |
|
Pre-IND/IDE or Equivalent | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Medeor Therapeutics |
 |
Clinical Trial, Phase 3 | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Leukemia, Acute Myeloid (AML) | Cancer Stem Cell | Antibody | Immune-Onc Therapeutics |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Leukemia, Acute Myeloid (AML) | Cancer Stem Cell | Small molecule therapy | UCSD |
|
Pre-IND/IDE or Equivalent | |
| Leukemia, Acute Myeloid (AML) | Embryonic Stem Cell | Donor cell therapy | UCSD |
|
Pre-IND/IDE or Equivalent | |
| Leukemia, Acute Myeloid (AML) | Cancer Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
Pre-IND/IDE or Equivalent | |
| Liver Disease | iPS Cell | Gene-modified, donor cell therapy | CHLA |
|
Development Candidate, Proof of Concept | |
| Liver Disease | iPS Cell | Diagnostic Test | UCSF |
|
Development Candidate, Proof of Concept | |
| Lung Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Melanoma | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
| Metabolic Disorders | Somatic Cell | Gene-modified, personalized cell therapy | Immusoft Corporation |
|
Pre-IND/IDE or Equivalent | |
| Multiple Myeloma | Adult Stem Cell | Personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
| Multiple Myeloma | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
| Multiple Myeloma | Adult Stem Cell | Gene-modified, personalized cell therapy | Poseida Therapeutics |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Skeletal/Smooth Muscle disorders | Adult Stem Cell | Small molecule therapy | Stanford |
|
Proof of Concept | |
| Muscular Dystrophy | Embryonic Stem Cell | Protein/peptide therapy | Juvena Therapeutics Inc |
|
Pre-IND/IDE or Equivalent | |
| Neurological Disorders | Embryonic Stem Cell | Donor cell therapy | UC Irvine |
|
Development Candidate, Proof of Concept | |
| Osteonecrosis | Adult Stem Cell | Small molecule therapy | UC Davis |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Ovarian Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
|
Pre-IND/IDE or Equivalent | |
| Ovarian Cancer | iPS Cell | Gene-modified, donor cell therapy | UCSD |
|
Development Candidate, Proof of Concept |
Pages
